C2i Genomics Platform
Whole-genome sequencing platform for minimal residual disease detection and cancer monitoring
Platform · OtherCompany source
Company profile
About C2i Genomics
C2i Genomics is a precision oncology company that leverages artificial intelligence and whole genome sequencing to transform cancer detection and monitoring. The company has developed a proprietary platform that analyzes the entire genome rather than targeted panels, enabling unprecedented sensitivity in detecting circulating tumor DNA (ctDNA) for minimal residual disease (MRD) monitoring and early cancer detection. C2i's technology addresses critical unmet needs in oncology by providing clinicians with actionable genomic intelligence to guide treatment decisions, monitor treatment response, and detect cancer recurrence earlier than traditional methods. By combining comprehensive whole genome analysis with advanced AI algorithms, C2i Genomics aims to improve patient outcomes through more precise, personalized cancer care. The company serves oncologists, cancer centers, and health systems seeking to implement cutting-edge genomic testing for their patients.
Company description C2i Genomics official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at C2i Genomics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- cancer
- cancer recurrence
- minimal residual disease
- oncology
Who it serves
- cancer centers
- health systems
- oncologists
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Predicting recurrence of Stage IA lung adenocarcinoma using ctDNA whole genome mutational signatures.The Journal of molecular diagnostics : JMD · Jul 30, 2026
Ultrasensitive ctDNA monitoring for organ preservation in patients with locally advanced rectal cancer.NPJ precision oncology · Dec 11, 2025
Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.European journal of cancer (Oxford, England : 1990) · Nov 1, 2024
Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.European urology · Oct 1, 2024
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.Nature communications · Oct 28, 2023
Expert Panel Curation of 113 Primary Mitochondrial Disease Genes for the Leigh Syndrome Spectrum.Annals of neurology · Oct 1, 2023
Clinical validation
Clinical-trial records
ctDNA and Organ Preservation/Pathologic CR in Rectal CancerNCT05629442 · Sponsor · NOT YET RECRUITING
Clinical Performance Evaluation of the C2i-TestNCT05221827 · Sponsor · TERMINATED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
ultra-sensitive ctDNA detection
minimal residual disease monitoring and early cancer detection
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from C2i Genomics
Recent articles published on C2i Genomics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.